Effects of aminoguanidine on serum advanced glycation endproducts, urinary albilmin excretion, mesangial expansion, and glomerular basement membrane thickening in Otsuka Long-Evans Tokushima Fatty rats

Diabetes Research and Clinical Practice

Volumn 34, Issue 3, 1997, Pages 127-133

  Yamauchi, Akira ^a   Takei, Izumi ^a   Makita, Zenji ^b   Nakamoto, Shinya ^a   Ohashi, Norimi ^a   Kiguchi, Hideko ^c   Ishii, Toshiharu ^d   Koike, Takao ^b   Saruta, Takao ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c Omori Red Cross Hospital   (Japan)

^d TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced glycation endproducts; Aminoguanidine; Diabetic nephropathy; Otsuka Long Evanss Tokushima Fatty rats

Indexed keywords

ALBUMIN; AMINOGUANIDINE; CHOLESTEROL; GLUCOSE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLOMERULUS BASEMENT MEMBRANE; GLYCATION; MALE; MESANGIUM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PROTEINURIA; RAT; THICKNESS;

ALBUMINURIA; ANIMALS; BASEMENT MEMBRANE; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GLOMERULAR MESANGIUM; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; RATS; RATS, INBRED STRAINS;

EID: 0031056385     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(96)01339-3     Document Type: Article

References (32)

1. [1] The Diabetes Control and Complication Trial Research Group. (1993) The effect of intensive treatment of diabetes on the development and progression on long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986.
2. [2] Brownlee, M., Cerami, A. and Vlassara, H. (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Eng. J. Med. 318, 1315-1321.
3. [3] Monnier, V.M., Vishwanath, V., Frank, K.E., Elmets, C.A., Dauchot, P. and Kohn, R.R. (1988) Relation between complication of type 1 diabetes mellitus and collagen-linked fluorescence. N. Eng. J. Med. 314, 403-408.
4. [4] Brownlee, M., Vlassara, H., Kooney, A., Ulrich, P. and Cerami, A. (1986) Aminoguanidine prevents diabetes-induced arterial protein cross-linking. Science 232, 1629-1632
5. [5] Soulis-Liparota, T., Cooper, M., Papazoglou, D., Clarke, B. and Jerums, G. (1991) Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes 40, 1328-1334.
6. [6] Edelstein, D. and Brownlee, M. (1992) Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 35, 96-97.
7. [7] Ellis, E.N. and Good, B.H. (1991) Prevention of glomerular basement thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 40, 1016-1019.
8. [8] Huijberts, M.S.P., Wolffenbuttel, B.H.R., Crijns, F.R.L., Kruseman, A.C.N., Bemelmans, H.AJ., Boudier, H.A.J.S. (1994) Aminoguanidine reduces regional albumin clearance but not urinary albumin excretion in streptozotocin-diabetic rats. Diabetologia 37, 10-14.
9. [9] Itakura, M., Yoshikawa, H., Bannai, C. et al. (1991) Aminoguanidine decreases urinary albumin and high-molecular-weight proteins in diabetic rats. Life Sci. 49, 889-897.
10. [10] Nicholls, K. and Mandel, T.E. (1989) Advanced glycosylation end-products in experimental murine diabetic nephropathy. Lab. Invest. 60, 486-494.
11. [11] Yagihashi, S., Kamijo, M., Baba, M., Yagihashi, N. and Nagai, K. (1992) Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 41, 47-52.
12. [12] Cameron, N.E., Cotter, M.A., Dines, K. and Love, A. (1992) Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 35, 946-950.
13. [13] Hammes, H.P., Martin, S., Federlin, K., Geisen, K. and Brownlee, M. (1991) Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl. Acad. Sci. USA, 88, 11 555-11 558.
14. [14] Hammes, H.P., Brownlee, M., Edelstein, D., Saleck, M., Martin, S. and Federlin, K. (1994) Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 37, 32-35.
15. [15] Kawano, K., Hirashima, T., Mon, S., Saitoh, Y., Kurosumi, M. and Natori, T. (1992) Spontaneous long-term hyperglycemic rat with diabetic complications, Otsuka Long-Evans Tokushima Fatty (OLETF) Strain. Diabetes 41, 1422-1428.
16. [16] Kawano, K., Hirashima, T., Mon, S., Kurosumi, M. and Saitoh, Y. (1991) A new rat strain with non-insulin dependent diabetes mellitus, 'OLETF'. Rat. News. Lett 25, 24-26.
17. [17] Soulis, T., Cooper, M., Layton, G., Allen, T. and Jerums, G. (1988) Aminoguanidine reduces tissue fluorescence but not albuminuria in diabetic rats. In: Ryal, R.G., (Ed.), Glycated Proteins in Diabetes Mellitus, Adelaide, Australia, University of Adelaide, pp. 310-320.
18. [18] Suzuki, D., Yagame, M., Kaneshige, H., Nomoto, Y. and Sakai, H. (1992) Analysis of the glomerular mesangium in patients with diabetic nephropathy using an automatic image analyzer. J. Jpn. Diab. Soc. 35, 825-830. (In Japanese).
19. [19] Jensen, E.B., Gundersen, H.J.G. and Osterby, R. (1979) Determination of membrane thickness distribution for orthogonal intercepts. J. Microsc. 115, 19-33.
20. [20] Ellis, E.N., Basgen, J.M., Mauer, S.M. and Steffes, M.W. (1985) Kidney biopsy technique and evaluation in diabetes mellitus, In: Lamer, F.J., Clarke, W.L. and Pohl, S.L. (eds), Methods of Diabetic Research, Vol. 2, Wiley, New York, pp. 633-648.
21. [21] Makita, Z., Vlassara, H., Cerami, A. and Bucala, R. (1992) Immunochemical detection of advanced glycosylation endproducts in vivo. J. Biol. Chem. 267, 5133-5138.
22. [22] Makita, Z., Bucala, R., Rayfield, EJ. et al. (1994) Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343, 1519-1522.
23. [23] Steffes, M.W. and Mauer, S.M. (1984) Diabetic glomerulopathy in humans and experimental animal models. Int Rev. Exp. Pathol. 26, 147-175.
24. [24] Cooper, M.E., Allen, T.J., Macmillan, P. et al. (1988) Effects of genetic hypertension on diabetic nephropathy in the rat-functional and structural characteristics. J. Hypertens. 6, 1009-1016.
25. [25] Hirose, K., Osterby, R., Nozawa, M. and Gunderson, H.J.G. (1982) Development of glomerular lesions in experimental long-term diabetes in the rat. Kidney. Int. 21, 689-695.
26. [26] Dolhofer-Bliesener, R., Lechner, B., Deppisch, R., Ritz, E. and Gerbitz, K.D. (1995) Immunological determination of advanced glycosylation end-products in human blood and urine. Nephrol. Dial. Transplant. 10, 657-664.
27. [27] Bucala, R., Makita, Z., Vega, G. et al. (1994) Modification of low density lipoprotein by advanced glycosylation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc. Natl. Acad. Sci. USA, 91, 9441-9445.
28. [28] Vlassara, H., Bucala, R., Striker, L. (1994) Pathological effects of advanced glycosylation:biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest 70, 138-151.
29. [29] Vlassara, H., Striker, U., Teichberg, S., Fuh, H., Li, Y.M. and Steffes, M. (1994) Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci. USA 91, 11 704-11 708.
30. [30] Yang, C.W., Vlassara, H., Peten, E.P., He, C.S., Striker, G.E. and Striker, U. (1994) Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc. Natl. Acad. Sci. USA 91, 9436-9440.
31. [31] Doi, T., Vlassara, H., Kirstein, M., Yamada, Y., Striker, G.E. and Striker, U. (1992) Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycation end products is mediated via platelet derived growth factor. Proc. Natl. Acad. Sci. USA 89, 2873-2877.
32. [32] Makita, Z., Vlassara, H., Rayfield, E. et al. (1992) A circulating marker of advanced glycosylation. Science 258, 851-853.